 |
|
|
|
|
|
Renagel® (sevelamer hydrochloride)
Renagel controls serum phosphorus levels without the concern of calcium or metal accumulation.
New KDOQI guidelines recommend Sevelamer as a first-line option for the reduction of phosphorus in Chronic Kidney Disease (CKD) patients on hemodialysis.1
|
 |
 |
|
|
|
|
|
|
|
|
 |
|
 |
 |
|
|
|
 |
|
|
 |
Renagel® (sevelamer hydrochloride) is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.
- Renagel is contraindicated in patients with hypophosphatemia or bowel obstruction.
- Caution should be exercised in patients with dysphagia, swallowing disorders, severe gastrointestinal (GI) motility disorders including severe constipation or major GI tract surgery.
- Common adverse events reported with Renagel include vomiting, nausea, diarrhea, dyspepsia, abdominal pain, and constipation.
- Other events reported include pruritus, rash, fecal impaction, and intestinal obstruction.
- Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take Renagel.
- Patients should be informed to take Renagel with meals and to adhere to their prescribed diets.
- Please see accompanying full Prescribing Information.
|
|
|
|
|
Genzyme Corporate
